For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Other revenue | - | -702* | 0 | 1,404 |
| Research and development | 200 | 484* | 177 | 192 |
| General and administrative | 514 | 1,312* | 547 | 915 |
| Gain on sale of baergic | - | 51* | - | - |
| Total operating expenses | - | 1,745* | 724 | 1,107 |
| Loss from operations | -714 | -2,447* | -724 | 297 |
| Interest income | 18 | 24* | 34 | 31 |
| Loss on common stock warrant liabilities | - | 0* | 0 | 0 |
| Change in fair value of warrant liabilities | -1 | -16* | 2 | -1 |
| Total other income | 19 | - | 32 | 32 |
| Net loss | -695 | -2,407* | -692 | 329 |
| Net loss attributable to non-controlling interests | 0 | -20* | - | -6 |
| Net loss attributable to common stockholders | -695 | -2,387 | -683 | 335 |
| Basic EPS | -0.21 | -0.789 | -0.21 | - |
| Basic Average Shares | 3,293,729 | 3,026,277 | 3,183,558 | 3,183,558 |
AVENUE THERAPEUTICS, INC. (ATXI)
AVENUE THERAPEUTICS, INC. (ATXI)